622 related articles for article (PubMed ID: 26438248)
41. Overcoming cellular multidrug resistance using classical nanomedicine formulations.
Kunjachan S; Błauż A; Möckel D; Theek B; Kiessling F; Etrych T; Ulbrich K; van Bloois L; Storm G; Bartosz G; Rychlik B; Lammers T
Eur J Pharm Sci; 2012 Mar; 45(4):421-8. PubMed ID: 21907796
[TBL] [Abstract][Full Text] [Related]
42. Different strategies to overcome multidrug resistance in cancer.
Saraswathy M; Gong S
Biotechnol Adv; 2013 Dec; 31(8):1397-407. PubMed ID: 23800690
[TBL] [Abstract][Full Text] [Related]
43. Nanomedicine: the promise and challenges in cancer chemotherapy.
Naguib YW; Cui Z
Adv Exp Med Biol; 2014; 811():207-33. PubMed ID: 24683034
[No Abstract] [Full Text] [Related]
44. Zinc Oxide Nanoparticles as Adjuvant To Facilitate Doxorubicin Intracellular Accumulation and Visualize pH-Responsive Release for Overcoming Drug Resistance.
Liu J; Ma X; Jin S; Xue X; Zhang C; Wei T; Guo W; Liang XJ
Mol Pharm; 2016 May; 13(5):1723-30. PubMed ID: 27070828
[TBL] [Abstract][Full Text] [Related]
45. Drug Delivery Nanoparticles in Treating Chemoresistant Tumor Cells.
Barrera G; Daga M; Ferrara B; Dianzani C; Pizzimenti S; Argenziano M; Cavalli R; Trotta F
Curr Med Chem; 2017; 24(42):4800-4815. PubMed ID: 27919217
[TBL] [Abstract][Full Text] [Related]
46. Overcoming multiple drug resistance in cancer using polymeric micelles.
Kesharwani SS; Kaur S; Tummala H; Sangamwar AT
Expert Opin Drug Deliv; 2018 Nov; 15(11):1127-1142. PubMed ID: 30324813
[TBL] [Abstract][Full Text] [Related]
47. Nanomedicines for combating multidrug resistance of cancer.
Zhu YX; Jia HR; Duan QY; Wu FG
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2021 Sep; 13(5):e1715. PubMed ID: 33860622
[TBL] [Abstract][Full Text] [Related]
48. Reversal of multidrug resistance by stimuli-responsive drug delivery systems for therapy of tumor.
Yin Q; Shen J; Zhang Z; Yu H; Li Y
Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1699-715. PubMed ID: 23611952
[TBL] [Abstract][Full Text] [Related]
49. Overcoming tumor cell chemoresistance using nanoparticles: lysosomes are beneficial for (stearoyl) gemcitabine-incorporated solid lipid nanoparticles.
Chen Z; Zheng Y; Shi Y; Cui Z
Int J Nanomedicine; 2018; 13():319-336. PubMed ID: 29391792
[TBL] [Abstract][Full Text] [Related]
50. Nanomedicines for Reactive Oxygen Species Mediated Approach: An Emerging Paradigm for Cancer Treatment.
Kwon S; Ko H; You DG; Kataoka K; Park JH
Acc Chem Res; 2019 Jul; 52(7):1771-1782. PubMed ID: 31241894
[TBL] [Abstract][Full Text] [Related]
51. [Progress in the study of micelle delivery system reversing multidrug resistance].
Diao YY; Han M; Chen DW; Gao JQ
Yao Xue Xue Bao; 2009 Jul; 44(7):710-5. PubMed ID: 19806907
[TBL] [Abstract][Full Text] [Related]
52. Nanotechnologies for the treatment of colon cancer: From old drugs to new hope.
Kotelevets L; Chastre E; Desmaële D; Couvreur P
Int J Pharm; 2016 Nov; 514(1):24-40. PubMed ID: 27863668
[TBL] [Abstract][Full Text] [Related]
53. In vivo dual-targeted chemotherapy of drug resistant cancer by rationally designed nanocarrier.
Wang Y; Zhao R; Wang S; Liu Z; Tang R
Biomaterials; 2016 Jan; 75():71-81. PubMed ID: 26491996
[TBL] [Abstract][Full Text] [Related]
54. Drug-delivering-drug approach-based codelivery of paclitaxel and disulfiram for treating multidrug-resistant cancer.
Mohammad IS; Teng C; Chaurasiya B; Yin L; Wu C; He W
Int J Pharm; 2019 Feb; 557():304-313. PubMed ID: 30599232
[TBL] [Abstract][Full Text] [Related]
55. Advances in combination therapies based on nanoparticles for efficacious cancer treatment: an analytical report.
Mignani S; Bryszewska M; Klajnert-Maculewicz B; Zablocka M; Majoral JP
Biomacromolecules; 2015 Jan; 16(1):1-27. PubMed ID: 25426779
[TBL] [Abstract][Full Text] [Related]
56. Not only P-glycoprotein: Amplification of the ABCB1-containing chromosome region 7q21 confers multidrug resistance upon cancer cells by coordinated overexpression of an assortment of resistance-related proteins.
Genovese I; Ilari A; Assaraf YG; Fazi F; Colotti G
Drug Resist Updat; 2017 May; 32():23-46. PubMed ID: 29145976
[TBL] [Abstract][Full Text] [Related]
57. Targeting tumor microenvironment with PEG-based amphiphilic nanoparticles to overcome chemoresistance.
Chen S; Yang K; Tuguntaev RG; Mozhi A; Zhang J; Wang PC; Liang XJ
Nanomedicine; 2016 Feb; 12(2):269-86. PubMed ID: 26707818
[TBL] [Abstract][Full Text] [Related]
58. TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance.
Zhao P; Li L; Zhou S; Qiu L; Qian Z; Liu X; Cao X; Zhang H
Mater Sci Eng C Mater Biol Appl; 2018 Mar; 84():108-117. PubMed ID: 29519418
[TBL] [Abstract][Full Text] [Related]
59. Formulation strategy to overcome multi-drug resistance (MDR).
Cho CW
Arch Pharm Res; 2011 Apr; 34(4):511-3. PubMed ID: 21544714
[No Abstract] [Full Text] [Related]
60. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
